Journal List > J Korean Ophthalmol Soc > v.54(7) > 1009417

Shin, Soo, and Jung: The Effect of Internal Limiting Membrane Peeling in Epiretinal Membrane Including Pseudolamellar Macular Hole

Abstract

Purpose

To report the effect and visual improvement of internal limiting membrane (ILM) peeling, and epiretinal mem-brane (ERM) peeling in symptomatic ERM with pseudolamellar macular hole.

Methods

This study included 27 eyes in 26 consecutive patients with ERM including pseudolamellar macular hole that un-derwent vitrectomy, ERM peeling, intravitreal gas tamponade, and maintained a face-down position for 7 days. ILM peel-ing was performed only in 13 eyes of 13 patients. The patients were divided into 2 groups: eyes with or without ILM peeling (14 eyes and 13 eyes, respectively) and the follow-up period was 12 months or more in all cases. The postoperative ana-tomic results based on optical coherence tomography (OCT) and improvement of best corrected visual acuity (BCVA) were retrospectively compared between the 2 groups.

Results

Anatomic closure after surgery was achieved in 11 eyes (78.6%) in the ILM without peeling group and in 12 eyes (92.3%) in the ILM with peeling group ( p = 0.596). The BCVA improved from 0.41 ± 0.31 (log MAR) to 0.33 ± 0.21 in the ILM without peeling group ( p = 0.479) and from 0.46 ± 0.41 (log MAR) to 0.28 ± 0.25 in the ILM with peeling group ( p = 0.001).

Conclusions

ILM peeling with the addition of ERM peeling is an effective technique for BCVA improvement in the ERM with pseudolamellar macular hole. Vitrectomy, ERM peeling, gas tamponade, and ILM peeling are important for anatomic and functional success in the ERM with pseudolamellar macular hole.

References

1. Gass JD. Lamellar macular hole: a complication of cystoid macular edema after cataract extraction: a clinicopathologic case report. Trans Am Ophthalmol Soc. 1975; 73:231–50.
2. Allen AW Jr, Gass JD. Contraction of a perifoveal epiretinal mem-brane simulating a macular hole. Am J Ophthalmol. 1976; 82:684–91.
crossref
3. Gass JDM. Vitreofoveal separation and lamellar hole formation Steroscopic atlas of macular disease: diagnosis and treatment. 4th ed. St Louis: CV Mosby;p. p 926–7.
4. Takahashi H, Kishi S. Tomographic features of a lamellar macular hole formation and a lamellar hole that progressed to a full-thick-ness macular hole. Am J Ophthalmol. 2000; 130:677–9.
crossref
5. Haouchine B, Massin P, Tadayoni R, et al. Diagnosis of macular pseudoholes and lamellar macular holes by optical coherence tomography. Am J Ophthalmol. 2004; 138:732–9.
crossref
6. Witkin AJ, Ko TH, Fujimoto JG, et al. Redefining lamellar holes and the vitreomacular interface: an ultrahigh-resolution optical co-herence tomography study. Ophthalmology. 2006; 113:388–97.
crossref
7. Chen JC, Lee LR. Clinical spectrum of lamellar macular defects in-cluding pseudoholes and pseudocysts defined by optical coherence tomography. Br J Ophthalmol. 2008; 92:1342–6.
crossref
8. Androudi S, Stangos A, Brazitikos PD. Lamellar macular holes: to-mographic features and surgical outcome. Am J Ophthalmol. 2009; 148:420–6.
crossref
9. Kinoshita T, Kovacs KD, Wagley S, Arroyo JG. Morphologic dif-ferences in epiretinal membranes on ocular coherence tomography as a predictive factor for surgical outcome. Retina. 2011; 31:1692–8.
crossref
10. Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes. Results of a pilot study. Arch Ophthalmol. 1991; 109:654–9.
crossref
11. Haouchine B, Massin P, Gaudric A. Foveal pseudocyst as the first step in macular hole formation: a prospective study by optical co-herence tomography. Ophthalmology. 2001; 108:15–22.
12. Michalewski J, Michalewska Z, Dzię gielewski K, et al. Evolution from macular pseudohole to lamellar macular hole - spectral do-main OCT study. Graefes Arch Clin Exp Ophthalmol. 2011; 249:175–8.
crossref
13. Fine BS. Limiting membranes of the sensory retina and pigment epithelium. An electron microscopic study. Arch Ophthalmol. 1961; 66:847–60.
crossref
14. de Bustros S, Thompson JT, Michels RG, et al. Vitrectomy for idio-pathic epiretinal membranes causing macular pucker. Br J Ophthalmol. 1988; 72:692–5.
crossref
15. de Bustros S, Rice TA, Michels RG, et al. Vitrectomy for macular pucker. Use after treatment of retinal tears or retinal detachment. Arch Ophthalmol. 1988; 106:758–60.
crossref
16. Mittleman D, Green WR, Michels RG, de la Cruz Z. Clinicopathologic correlation of an eye after surgical removal of an epiretinal membrane. Retina. 1989; 9:143–7.
crossref
17. Witkin AJ, Castro LC, Reichel E, et al. Anatomic and visual out-comes of vitrectomy for lamellar macular holes. Ophthalmic Surg Lasers Imaging. 2010; 41:418–24.
crossref
18. Michalewska Z, Michalewski J, Odrobina D, et al. Surgical treat-ment of lamellar macular holes. Graefes Arch Clin Exp Ophthalmol. 2010; 248:1395–400.
crossref
19. Garretson BR, Pollack JS, Ruby AJ, et al. Vitrectomy for a sympto-matic lamellar macular hole. Ophthalmology. 2008; 115:884–6.
crossref
20. Haritoglou C, Gass CA, Schaumberger M, et al. Macular changes after peeling of the internal limiting membrane in macular hole surgery. Am J Ophthalmol. 2001; 132:363–8.
crossref
21. Uemoto R, Yamamoto S, Takeuchi S. Epimacular proliferative re-sponse following internal limiting membrane peeling for idio-pathic macular holes. Graefes Arch Clin Exp Ophthalmol. 2004; 242:177–80.
crossref
22. Simddy WE, Feuer W, Cordahi G. Internal limiting membrane peel-ing in macular hole Surgery. Ophthalmology. 2001; 108:1471–8.
crossref
23. Engelbrecht NE, Freeman J, Sternberg Jr P, et al. Retinal pigment epithelial changes after macular hole surgery with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol. 2002; 133:89–94.
crossref
24. Gale JS, Proulx AA, Gonder JR, et al. Comparison of the in vitro toxicity of green to that of trypan blue in human retinal pigment ep-ithelium cell cultures. Am J Ophthalmol. 2004; 138:64–9.
25. Umeura A, Kanda S, Sakamoto Y, Kita H. Visual field defects after uneventful vitrectomy for epiretinal membrane with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol. 2003; 136:252–7.
26. Kwok AK, Lai TY, Yuen KS, et al. Macular hole surgery with or without indocyanine green stained internal limiting peeling. Clin Exp Ophthalmol. 2003; 31:470–5.
27. Park UC, Park KH, Yu YS, Chung H. Comparision of indocyanine green and triamcinolone acetonide for internal limiting membrane peeling in macular hole. J Korean Ophthalmol Soc. 2005; 46:1995–2003.
28. Lee SJ, Jang SY, Moon D, et al. Long-term surgical outcomes after vitrectomy for symptomatic lamellar macular holes. Retina. 2012; 32:1743–8.
crossref
29. Cho WB, Shin HJ, Moon JW, Kim HC. Four cases of pars plana vi-trectomy for treatment of symptomatic lamellar macular holes. J Korean Ophthalmol Soc. 2009; 50:1427–31.
crossref

Figure 1.
(A) Preoperative OCT image with visual acuity log MAR 0.52. This image shows the ERM and fulfills the criteria for OCT diagnosis of lamellar macular hole (1) irregular foveal contour; (2) dehiscence in the inner fovea; (3) separation of the inner from the outer fovea retinal layers, leading to an intraretinal split; (4) absence of a full-thickness foveal defect. (B) OCT at 12 months after operation with visual acuity log MAR 0.22. This image shows the postoperative normalization of the fovea contour.
jkos-54-1038f1.tif
Figure 2.
(A) Preoperative OCT image with visual acuity log MAR 0.40. This image shows the ERM and fulfills the OCT diagnosis of macular pseudohole (1) centripetal contraction of an ERM; (2) steepened foveal pit; (3) well-demarcated round or oval shape. (B) OCT at 12 months after operation with visual acuity log MAR 0.22. This image shows the postoperative normalization of the fovea contour.
jkos-54-1038f2.tif
Table 1.
Patient’s characteristics, Visual acuity and Macula status as assessed by optical coherence tomography
Patient No. Sex/Age (years) Preop Lens status Preop BCVA Final BCVA Follow-up (months) ILM peeling Postop Macula status
1 F/71 IOL 20/100 20/100 21 No Normalized
2 F/62 Phakic 20/50 20/40 32 No Normalized
3 F/73 Phakic 20/500 20/63 13 No Normalized
4 M/64 Phakic 20/30 20/50 17 No Normalized
5 F/53 Phakic 20/25 20/25 12 No Improved
6 M/66 IOL 20/50 20/100 21 No Normalized
7 F/70 IOL 30/20 20/50 18 No Normalized
8 F/68 IOL 20/63 20/40 12 No Normalized
9 M/71 Phakic 20/50 20/20 14 No Normalized
10 M/71 Phakic 20/30 20/25 12 No Normalized
11 F/74 Phakic 20/40 20/50 14 No Improved
12 F/74 Phakic 20/50 20/40 13 No Normalized
13 F/53 Phakic 20/63 20/40 38 No Progressed
14 F/64 Phakic 20/40 20/30 12 No Normalized
15 F/50 Phakic 20/25 20/25 21 Yes Normalized
16 M/69 Phakic 20/25 20/20 36 Yes Normalized
17 F/70 IOL 20/50 20/30 13 Yes Normalized
18 F/62 Phakic 20/63 20/32 13 Yes Normalized
19 F/71 IOL 20/1000 20/100 12 Yes Normalized
20 F/67 Phakic 20/50 20/40 15 Yes Normalized
21 F/55 Phakic 20/40 20/30 12 Yes Normalized
22 F/81 Phakic 20/40 20/30 13 Yes Unchanged
23 M/75 Phakic 20/50 20/30 12 Yes Normalized
24 F/56 Phakic 20/100 20/32 14 Yes Normalized
25 F/54 Phakic 20/63 20/30 23 Yes Normalized
26 F/46 Phakic 20/50 20/32 23 Yes Normalized
27 F/73 IOL 20/30 20/30 12 Yes Normalized

BCVA = best corrected visual acuity; ILM = internal limiting membrane; IOL = intraocular lens.

Table 2.
Patient’s demographic findings in two groups
Group 1* Group 2 Total
Sex (M : F) 4 : 10 (14) 2 : 11 (13) 6 : 21 (27)
Age (years) 66.7 (53-74) 63.7 (46-81) 65.3
Phakic : Pseudophakic 10 : 4 10 : 3 20 : 7
Combined cataract surgery 10 (71.4%) 10 (76.9%) 20 (74.1%)
Follow-up (months) 17.9 (12-32) 16.9 (12-36) 17.4

* No ILM peeling

ILM peeling.

Table 3.
Comparision of best-corrected visual acuity in two group
Group 1* Group 2 p-value
Preoperative BCVA (log MAR) 0.41 ± 0.31 0.46 ± 0.41 0.882§
Final BCVA (log MAR) 0.33 ± 0.21 0.28 ± 0.25 0.082§
p-value 0.479 0.001

Values are presented as mean ± SD. BCVA = best corrected visual acuity.

* No ILM peeling

ILM peeling

Wilcoxon signed rank test

§ Mann-Whitney test.

Table 4.
Final visual acuity changing degree in two groups
Same or <2 snellen lines improvement >2 snellen lines improvement >2 snellen lines worsening Total
Group 1* 5 (35.7%) 5 (35.7%) 4 (28.6%) 14
Group 2 4 (30.8%) 9 (69.2%) 0 (0%) 13
p‐ value 0.074 27

* No ILM peeling

ILM peeling

Chi-square test.

Table 5.
Comparision of anatomical success and functional success in two groups
Group 1* Group 2 p-value
Anatomical success 11 (14) 78.6% 12 (13) 92.3% 0.596
Functional success 5 (14) 35.7% 9 (13) 69.2% 0.021

* No ILM peeling

ILM peeling

Fisher’s exact test.

Table 6.
Comparision of mean change in best-corrected visual acuity at 3 and 6 months
Group 1* Group 2 p-value
Mean change in BCVA at 3 months (log MAR) 0.011 ± 0.345 -0.126 ± 0.211 0.138§
Mean change in BCVA at 6 months (log MAR) -0.067 ± 0.289 -0.164 ± 0.151 0.068§
p-value 0.141 0.028

Values are presented as mean ± SD. BCVA = best corrected visual acuity.

* No ILM peeling

ILM peeling

Wilcoxon signed rank test

§ Mann-Whitney test.

TOOLS
Similar articles